需要大量输血方案的患者中输注不相容A型血浆的结局:东部创伤外科协会多中心研究
该研究为东部创伤外科协会多中心试验,收集8家创伤中心2012年1月至2016年8月接受大量输血方案急诊释放血浆的创伤患者(年龄≥15岁)的登记和血库数据。1,536例患者中92%接受相容血浆,8%接受不相容A型血浆。不相容组穿透伤比例更高(48% vs 36%,p=0.01),4小时血浆输注量更多(中位数9 vs 5,p<0.001),住院总血浆量更多(11 vs 9,p=0.03)。未报告溶血性输血反应。两组急性呼吸窘迫综合征、血栓栓塞事件、脓毒症、急性肾衰竭及6小时、24小时、28天或出院死亡率均无显著差异。多因素回归显示不相容输血不是死亡或发病的独立决定因素。
要点
- 在大量输血方案中,对血型B或AB的创伤患者输注不相容A型血浆,未报告溶血性输血反应。
- 不相容组与相容组28天或出院死亡率相似(38% vs 35%,p=0.486),6小时(17% vs 15%,p=0.775)和24小时(25% vs 23%,p=0.544)死亡率也无显著差异。
- 不相容组4小时血浆输注量中位数更多(9 vs 5,p<0.001),住院总血浆量也更多(11 vs 9,p=0.03)。
- 两组急性呼吸窘迫综合征(6% vs 8%,p=0.589)、血栓栓塞事件(9% vs 7%,p=0.464)、脓毒症(6% vs 8%,p=0.589)、急性肾衰竭(8% vs 8%,p=0.860)无显著差异。
- 多因素回归显示损伤严重度评分、年龄较大和4小时红细胞输注量更多与28天或出院死亡独立相关,不相容输血不是死亡或发病的独立决定因素。
适用人群与场景
- 8家创伤中心收治的创伤患者,年龄≥15岁,接受大量输血方案中的急诊释放血浆输注,时间范围为2012年1月至2016年8月。
诊断标准与关键阈值
- 不相容A型血浆定义为将A型血浆输注给血型B或AB的患者。
研究设计与关键结果
- 研究类型为东部创伤外科协会多中心试验,收集8家创伤中心登记和血库数据,共识别1,536例患者,92%接受相容血浆,8%接受不相容A型血浆。
- 不相容组穿透伤比例更高(48% vs 36%,p=0.01),4小时血浆输注量中位数更多(9 vs 5,p<0.001),住院总血浆量更多(11 vs 9,p=0.03)。
- 未报告溶血性输血反应;相容组报告2例输血相关急性肺损伤事件。
- 不相容组与相容组急性呼吸窘迫综合征(6% vs 8%,p=0.589)、血栓栓塞事件(9% vs 7%,p=0.464)、脓毒症(6% vs 8%,p=0.589)、急性肾衰竭(8% vs 8%,p=0.860)无显著差异。
- 不相容组与相容组6小时死亡率(17% vs 15%,p=0.775)、24小时死亡率(25% vs 23%,p=0.544)、28天或出院死亡率(38% vs 35%,p=0.486)相似。
- 多因素回归显示损伤严重度评分、年龄较大和4小时红细胞输注量更多与28天或出院死亡独立相关;损伤严重度评分和4小时红细胞输注量更多是发病的预测因素;不相容输血不是死亡或发病的独立决定因素。
证据类型、等级与局限
- 证据类型为治疗性研究,证据等级为level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在大量输血方案中对血型B和AB的患者输注A型血浆似乎与发病率或死亡率显著增加无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: With a relative shortage of type AB plasma, many centers have converted to type A plasma for resuscitation of patients whose blood type is unknown. The goal of this study is to determine outcomes for trauma patients who received incompatible plasma transfusions as part of a massive transfusion protocol (MTP).
METHODS: As part of an Eastern Association for the Surgery of Trauma multi-institutional trial, registry and blood bank data were collected from eight trauma centers for trauma patients (age, ≥ 15 years) receiving emergency release plasma transfusions as part of MTPs from January 2012 to August 2016. Incompatible type A plasma was defined as transfusion to patient blood type B or type AB.
RESULTS: Of the 1,536 patients identified, 92% received compatible plasma transfusions and 8% received incompatible type A plasma. Patient characteristics were similar except for greater penetrating injuries (48% vs 36%; p = 0.01) in the incompatible group. In the incompatible group, patients were transfused more plasma units at 4 hours (median, 9 vs. 5; p < 0.001) and overall for stay (11 vs. 9; p = 0.03). No hemolytic transfusion reactions were reported. Two transfusion-related acute lung injury events were reported in the compatible group. Between incompatible and compatible groups, there was no difference in the rates of acute respiratory distress syndrome (6% vs. 8%; p = 0.589), thromboembolic events (9% vs. 7%; p = 0.464), sepsis (6% vs. 8%; p = 0.589), or acute renal failure (8% vs. 8%, p = 0.860). Mortality at 6 (17% vs. 15%, p = 0.775) and 24 hours (25% vs. 23%, p = 0.544) and at 28 days or discharge (38% vs. 35%, p = 0.486) were similar between groups. Multivariate regression demonstrated that Injury Severity Score, older age and more red blood cell transfusion at 4 hours were independently associated with death at 28 days or discharge; Injury Severity Score and more red blood cell transfusion at 4 hours were predictors for morbidity. Incompatible transfusion was not an independent determinant of mortality or morbidity.
CONCLUSION: Transfusion of type A plasma to patients with blood groups B and AB as part of a MTP does not appear to be associated with significant increases in morbidity or mortality.
LEVEL OF EVIDENCE: Therapeutic study, level IV.
参考来源
- Stevens WT, Morse BC, Bernard A, et al. Incompatible type A plasma transfusion in patients requiring massive transfusion protocol: Outcomes of an Eastern Association for the Surgery of Trauma multicenter study. J Trauma Acute Care Surg. 2017. PMID: 28452877. doi:10.1097/TA.0000000000001532
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。